Clinical Trial Update: Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating vorinostat for ACTH-producing pituitary adenomas in Cushing's disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cushing Disease

Drugs mentioned

• Vorinostat (vorinostat)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Cushing's Disease | Phase 2 | Status: WITHDRAWN